Dr. Vogel helped found New Jersey’s first dedicated pediatric neuro-oncology lab at the Center for Discovery and Innovation with support from Tackle Kids Cancer and Tommy Strong Foundation. Research from this lab has focused on embryonal tumors with multilayered rosettes (ETMR) which is a rare CNS malignancy affecting young children that carries a very poor prognosis. Treatment modalities include surgical resection, radiotherapy, and chemotherapy but effective, biologically based therapies for this tumor are needed to prolong survival.
Continuing Research for Rare Brain Tumors
“To continue advancing our understanding of and ability to treat neuro-oncologic issues, we need to build a pipeline from research to clinical applications,” said Dr. Vogel. “Dr. Hanson and I plan to explore treatments for rare brain tumors, specifically embryonal tumors with multilayered rosettes. These exceptionally aggressive tumors usually affect children younger than 4 years of age, with an average survival rate of 6 months to 1 year following diagnosis. I see it as my responsibility to help advance our medical knowledge of these potentially devastating diseases as much as possible, and I feel privileged to touch the lives of every pediatric patient who requires care.”
SOURCE: New Pediatric Neuro-Oncology Research...
Dr. Vogel's Research
A surgeon at New Jersey Brain and Spine for 5 years, Dr. Vogel has conducted research in laboratories at Princeton, Columbia, Harvard, and the Howard Hughes Medical Institute. He has also led his own National Institutes of Health–funded lab at Cincinnati Children’s Hospital.
- Drs. Timothy Vogel, Derek Hanson establish neuro-oncology research laboratory
- The Children’s Cancer Institute Launches Groundbreaking Trial for Pediatric Brain Cancer Patients
- Tommy Strong Foundation: Impact
- New Pediatric Neuro-Oncology Research Lab Established at Hackensack University Medical Center
- Pediatric Neuro-Oncology Lab
- Hackensack Meridian Health Opens Pediatric Neuro-Oncology Laboratory at the Center for Discovery & Innovation (CDI)
- A modified IRS-III chemotherapy regimen leads to prolonged survival in children with embryonal tumor with multilayer rosettes
